Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia.
Alpesh N AminJesse D OrtendahlAmanda L HarmonSiddhesh A KamatRobert A StellhornSandra L ChaseShirin V SundarPublished in: Current medical research and opinion (2018)
Results demonstrate that tolvaptan is used infrequently among patients with HF and HN, and is utilized among sicker patients. Tolvaptan accounted for 0.3% of total spending on management of inpatient visits with HF and HN, and had a marginal impact on hospital budget when compared with fluid restriction for HN correction. Availability of tolvaptan can provide an additional therapeutic option for sodium correction.